Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2012 1
2014 3
2015 8
2016 6
2017 7
2018 14
2019 29
2020 45
2021 42
2022 38
2023 43
2024 21

Text availability

Article attribute

Article type

Publication date

Search Results

222 results

Results by year

Filters applied: . Clear all
Page 1
Pexidartinib.
[No authors listed] [No authors listed] 2019 Oct 10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2019 Oct 10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31869194 Free Books & Documents. Review.
Pexidartinib is an orally available small molecule multi-kinase inhibitor that is used as an antineoplastic agent in the treatment of tenosynovial giant cell tumors. Pexidartinib is associated with a high rates of serum aminotransferase and alkaline phosphatase elev …
Pexidartinib is an orally available small molecule multi-kinase inhibitor that is used as an antineoplastic agent in the treatment of …
Pexidartinib.
[No authors listed] [No authors listed] 2020 Apr 20. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2020 Apr 20. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 32352705 Free Books & Documents. Review.
No information is available on the clinical use of pexidartinib during breastfeeding. Because pexidartinib is over 99% bound to plasma proteins, the amount in milk is likely to be low. However, the manufacturer recommends that breastfeeding be discontinued during …
No information is available on the clinical use of pexidartinib during breastfeeding. Because pexidartinib is over 99% bound t …
Pexidartinib: First Approval.
Lamb YN. Lamb YN. Drugs. 2019 Nov;79(16):1805-1812. doi: 10.1007/s40265-019-01210-0. Drugs. 2019. PMID: 31602563 Free PMC article. Review.
This approval was based on positive results from the phase III ENLIVEN trial. Pexidartinib is being investigated in various malignancies as monotherapy or combination therapy. This article summarizes the milestones in the development of pexidartinib leading to its f …
This approval was based on positive results from the phase III ENLIVEN trial. Pexidartinib is being investigated in various malignanc …
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.
Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S, Blay JY, Alcindor T, Ganjoo K, Martín-Broto J, Ryan CW, Thomas DM, Peterfy C, Healey JH, van de Sande M, Gelhorn HL, Shuster DE, Wang Q, Yver A, Hsu HH, Lin PS, Tong-Starksen S, Stacchiotti S, Wagner AJ; ENLIVEN investigators. Tap WD, et al. Lancet. 2019 Aug 10;394(10197):478-487. doi: 10.1016/S0140-6736(19)30764-0. Epub 2019 Jun 19. Lancet. 2019. PMID: 31229240 Free PMC article. Clinical Trial.
Part one was a double-blind study in which patients with symptomatic, advanced TGCT for whom surgery was not recommended were randomly assigned via an integrated web response system (1:1) to the pexidartinib or placebo group. Individuals in the pexidartinib group re …
Part one was a double-blind study in which patients with symptomatic, advanced TGCT for whom surgery was not recommended were randomly assig …
Pexidartinib in the Management of Advanced Tenosynovial Giant Cell Tumor: Focus on Patient Selection and Special Considerations.
Vaynrub A, Healey JH, Tap W, Vaynrub M. Vaynrub A, et al. Onco Targets Ther. 2022 Jan 13;15:53-66. doi: 10.2147/OTT.S345878. eCollection 2022. Onco Targets Ther. 2022. PMID: 35046667 Free PMC article. Review.
While the introduction of pexidartinib allows clinicians to avoid the significant morbidity associated with traditional treatment options, there are also defined risks associated with pexidartinib treatment. ...The purpose of this literature review is to identify th …
While the introduction of pexidartinib allows clinicians to avoid the significant morbidity associated with traditional treatment opt …
Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor.
Gelderblom H, de Sande MV. Gelderblom H, et al. Future Oncol. 2020 Oct;16(29):2345-2356. doi: 10.2217/fon-2020-0542. Epub 2020 Jul 23. Future Oncol. 2020. PMID: 32700568 Free article. Review.
Pexidartinib is an orally administered small molecule tyrosine kinase inhibitor. ...Side effects associated with pexidartinib are generally manageable; however, there is a risk of potentially life-threatening mixed or cholestatic hepatotoxicity and pexidartinib …
Pexidartinib is an orally administered small molecule tyrosine kinase inhibitor. ...Side effects associated with pexidartinib …
Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy.
Palmerini E, Longhi A, Donati DM, Staals EL. Palmerini E, et al. Expert Rev Anticancer Ther. 2020 Jun;20(6):441-445. doi: 10.1080/14737140.2020.1757441. Epub 2020 Apr 22. Expert Rev Anticancer Ther. 2020. PMID: 32297819 Review.
AREAS COVERED: This article reviews the pharmacological properties, clinical efficacy, and safety of pexidartinib. EXPERT OPINION: Pexidartinib was effective with an acceptable safety profile for advanced TGCT in phase I-III studies. ...TGCT significantly impairs pa …
AREAS COVERED: This article reviews the pharmacological properties, clinical efficacy, and safety of pexidartinib. EXPERT OPINION: …
Pexidartinib (TURALIO): The First FDA-Indicated Systemic Treatment for Tenosynovial Giant Cell Tumor.
Monestime S, Lazaridis D. Monestime S, et al. Drugs R D. 2020 Sep;20(3):189-195. doi: 10.1007/s40268-020-00314-3. Drugs R D. 2020. PMID: 32617868 Free PMC article. Review.
Clinicians using pexidartinib should monitor for liver-related adverse events, which may require treatment interruption, dose reduction, or treatment discontinuation. Pexidartinib provides a novel non-surgical treatment option for patients with tenosynovial giant ce …
Clinicians using pexidartinib should monitor for liver-related adverse events, which may require treatment interruption, dose reducti …
CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment.
Fujiwara T, Yakoub MA, Chandler A, Christ AB, Yang G, Ouerfelli O, Rajasekhar VK, Yoshida A, Kondo H, Hata T, Tazawa H, Dogan Y, Moore MAS, Fujiwara T, Ozaki T, Purdue E, Healey JH. Fujiwara T, et al. Mol Cancer Ther. 2021 Aug;20(8):1388-1399. doi: 10.1158/1535-7163.MCT-20-0591. Epub 2021 Jun 4. Mol Cancer Ther. 2021. PMID: 34088832 Free PMC article.
Considering current advances in understanding the role of the inflammatory tumor microenvironment, targeting the components of the sarcoma microenvironment, such as TAMs, is a viable strategy. Here, we investigated the effect of PLX3397 (pexidartinib) as a potent inhibitor …
Considering current advances in understanding the role of the inflammatory tumor microenvironment, targeting the components of the sarcoma m …
Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors.
Baldi GG, Gronchi A, Stacchiotti S. Baldi GG, et al. Expert Rev Clin Pharmacol. 2020 Jun;13(6):571-576. doi: 10.1080/17512433.2020.1771179. Epub 2020 Jun 1. Expert Rev Clin Pharmacol. 2020. PMID: 32478598 Review.
EXPERT OPINION: CSFR1 inhibitors have opened a new avenue for treatment of TGCT patients. Pexidartinib is the first-in-class FDA approved agent for symptomatic locally advanced TGCT, based on a phase III study where pexidartinib showed high anti-tumor activity, impr …
EXPERT OPINION: CSFR1 inhibitors have opened a new avenue for treatment of TGCT patients. Pexidartinib is the first-in-class FDA appr …
222 results